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Abstract: Raltegravir, the only integrase (IN) inhibitor approved for use in HIV therapy, has 
recently been licensed. Raltegravir inhibits HIV-1 replication by blocking the IN strand transfer 
reaction. More than 30 mutations have been associated with resistance to raltegravir and other IN 
strand transfer inhibitors (INSTIs). The majority of the mutations are located in the vicinity of 
the IN active site within the catalytic core domain which is also the binding pocket for INSTIs. 
High-level resistance to INSTIs primarily involves three independent mutations at residues 
Q148, N155, and Y143. The mutations significantly affect replication capacity of the virus and 
are often accompanied by other mutations that either improve replication fitness and/or increase 
resistance to the inhibitors. The pattern of development of INSTI resistance mutations has been 
extensively studied in vitro and in vivo. This has been augmented by cell-based phenotypic 
studies and investigation of the mechanisms of resistance using biochemical assays. The recent 
elucidation of the structure of the prototype foamy virus IN, which is closely related to HIV-1, in 
complex with INSTIs has greatly enhanced our understanding of the evolution and mechanisms 
of IN drug resistance.
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The management of HIV-1 infection and drug  
resistance
Over 20 antiretroviral drugs (ARVs) have been licensed for the treatment of 
HIV-1 infection in the past 25 years.1 This has significantly improved the prognosis of 
HIV-infected individuals and reduced the mortality and morbidity rates worldwide.2,3 
The initial class of drugs approved for HIV-1 therapy were the nucleoside reverse 
transcriptase inhibitors (NRTIs) which are nucleoside analogs that inhibit DNA syn-
thesis by acting as chain terminators.4 Subsequently, further classes of ARVs with 
different inhibitory mechanisms and/or targets were approved for use against HIV-1, 
these being non-NRTIs and protease inhibitors (PIs).5,6 All three classes target viral 
enzymes required for HIV-1 viral replication, namely reverse transcriptase and pro-
tease. Therefore, it is not surprising that drug-resistant variants eventually emerge 
against these agents due to HIV’s high mutation rate and lack of a proofreading 
mechanism. The occurrence of drug resistance was a particular problem in the early 
years of ARV therapy when the drugs were used separately. This led to the idea of 
using no less than three different drugs belonging to at least two different classes to 
increase the genetic barrier to resistance development in what is termed highly active 
antiretroviral therapy (HAART).Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Nonetheless, the emergence of drug-resistant HIV-1 
variants in patients undergoing HAART remains a major 
reason for treatment failure in HIV-1 therapy. Several fac-
tors contribute to treatment failure in the era of HAART, 
and these include poor adherence due to adverse effects 
associated with the drugs, high pill burden, or irregular sup-
ply of the ARVs particularly in resource-poor countries. In 
addition, the transmission of drug-resistant viral strains can 
compromise and limit the effectiveness of first-line treatment 
regimens. The past few years have seen the introduction of 
three new classes of ARVs and second-generation drugs or 
variants of the original classes, such as the NRTI-variant 
tenofovir, which possess different inhibitory mechanisms 
and/or fewer adverse effects. The three new classes are fusion 
inhibitors, entry inhibitors, and integrase (IN) inhibitors. 
This review focuses on the pattern of resistance development 
to IN inhibitors as currently understood at the molecular 
and structural level.
HIV-1 IN and integration
Following entry of HIV into a host cell, the virus synthesizes 
a double-stranded (ds) DNA copy of its RNA genome. The 
viral DNA is then irreversibly inserted into the host genome 
in a process called integration.7,8 This is a defining step in   
the virus life cycle as it establishes a perpetual source of 
viral progeny for the lifetime of the cell. Integration is 
mediated by the virally encoded enzyme IN, and targeting 
this protein or its actions is a useful antiviral strategy.9–13 
IN performs two main enzymatic reactions to facilitate the 
integration of HIV DNA into the host genome. The first 
reaction, termed 3′ processing, prepares the viral DNA ends 
for insertion into target DNA by removing a pair of nucle-
otides at the 3′ end of both viral DNA strands (Figure 1). 
This exposes a 3′ hydroxyl group on the terminal adenosine 
of the conserved CA dinucleotide. The 3′ processing occurs 
in the cytoplasm within a high-molecular-weight preintegra-
tion complex (PIC) made up of viral DNA together with 
viral and cellular proteins.14–18 The 3′ processing step is 
followed by the active transfer of the PIC into the nucleus, 
a move facilitated by the interaction of the PIC with nucleo-
pore complex proteins.19
Following nuclear transfer, IN performs the second of its 
enzymatic reactions, namely strand transfer (Figure 1). The 
exposed 3′ hydroxyl groups at the viral DNA ends are used 
to attack a pair of phosphodiester bonds in the target DNA at 
sites that are five base pairs (bp) apart, resulting in ligation 
of the viral DNA strands to host cell genomic DNA. Finally, 
the unpaired viral CA dinucleotides on the nonligated viral 
DNA strands are removed, and the resulting five bp gaps on 
either end of the newly formed junctions are repaired and 
ligated. These reactions are believed to be performed by host 
DNA repair enzymes.20 No specific DNA sequence motif has 
been shown to be a preferred target for HIV-1 integration, but 
HIV-1 has been shown to selectively insert its DNA within 
transcriptional units of actively expressed host genes, whereas 
gamma-retroviruses, such as MLV , prefer to integrate their 
DNA upstream of host genes in the promoter region.21–24
IN is encoded by the C-terminal region of the HIV-1 pol 
gene and is a 288 amino acid-long protein that is convention-
ally divided into three structural and functional domains, 
namely N-terminal domain (NTD), catalytic core domain 
(CCD), and C-terminal domain (CTD). The structure of the 
entire HIV-1 IN has proved elusive; however, the structures of 
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Figure 1 HIv-1 DNA integration. HIv-1 virus synthesizes a dsDNA (red) copy 
of its RNA genome following entry of the virus into host cell cytoplasm. HIv-1 
integrase removes 3′ end GT dinucleotides on both viral DNA ends to expose a 
3′ hydroxyl group on terminal adenosines by 3′ processing. The 3′ processed viral 
DNA is then imported into the nucleus where strand transfer occurs resulting in 
the integration of the two viral DNA ends into host DNA (black) at positions five 
base pairs (bp) apart. Host DNA repair enzymes then cleave unpaired viral CA 
dinucleotides, fill in the five bp gaps (green), and ligate the DNA ends.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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its three domains have been determined separately as well as 
two-domain fragments.25–27 These studies have revealed that 
the NTD encompasses IN residues 1–49 and is made up of 
a triplet of α-helices, containing a double histidine/cysteine 
(H12-H16-C40-C43) zinc-binding motif. The motif plays a role in 
the dimerization of IN monomers and the binding of cellular 
factors.28 IN residues 50–212 make up the CCD which con-
tains the IN active site composed of a triad of acidic residues 
D64, D116, and E152, also called the DDE motif. The motif 
is essential for the coordination of divalent metal ions (Mg2+ 
or Mn2+) that are essential for IN enzymatic functions.28 The 
CTD, residues 213–288, contains SH3 domains that nonspe-
cifically bind to DNA.29 It is believed that the functional entity 
of HIV-1 IN is a tetramer assembled from two symmetrical 
dimers each bound to one of the viral DNA ends.30 Elucidation 
of the structure of full-length HIV-1 IN and its mode of action 
has recently benefited from the determination of the crystal 
structure of prototype foamy virus (PFV) IN tetramer in 
complex with 3′ processed viral DNA ends.30,31 This IN–DNA 
complex is called an intasome and is the minimal structure 
required for integration into target DNA. The structural model 
of HIV-1 intasome based on the PFV intasome shows the 
two viral DNA ends engaged by the active site to be ∼18Å 
apart which is equivalent to a five bp distance, thus validating 
the intasome as the integration functional unit.30 The intasome 
is also the preferred target for inhibitors of IN, rather than the 
unbound enzyme, indicating a direct or indirect involvement 
of the viral DNA ends in inhibitor binding.
Inhibitors of HIV-1 IN
To date, only one IN inhibitor has been licensed for use in 
HIV-1 treatment; this being raltegravir which is marketed 
under the brand name Isentress® (Merck & Co., Inc., White 
house station, NJ) and was also formerly called MK-0518. 
Raltegravir, which was approved for use by the US Food 
and Drug Administration in 2007, is a diketo acid (DKA) 
analog. A signature feature of DKAs is a β-hydroxy ketone 
moiety (Figure 2A), and the compounds were the first 
molecules to be reported as potent and specific IN strand 
transfer inhibitors (INSTIs). The first two DKA compounds 
to enter clinical trials were S-1360 and L-870,810, but these 
agents demonstrated poor efficacy and toxicity, respectively, 
and were not developed further.32 However, another INSTI, 
namely elvitegravir, is in the late stages of clinical develop-
ment and is expected to be approved for clinical use soon, 
with several others at different stages of development. 
Elvitegravir is structurally similar to quinolone antibiotics, 
but like raltegravir, it contains a β-hydroxy ketone moiety 
(Figure 2B). The crystal   structures of PFV in complex with 
the inhibitors, as well as the structural models of the HIV 
intasome, show that the oxygen atoms of the β-hydroxy 
ketone moiety chelate the divalent metal ions that are 
coordinated by the DDE motif of the IN active site, thereby 
impeding their participation in the DNA strand transfer 
reaction (Figure 3A, B). At the same time, the halobenzyl 
moieties of the inhibitors end stacked up against the cytosine 
of the CA dinucleotide which forces the reactive 3′ hydroxyl 
group of the terminal adenosine away from the active site 
(Figure 3B). The drugs also make contact with residues Q146 
and R231.30 In addition, raltegravir interacts with N117, 
Y143, N144, and P145, while elvitegravir makes only one 
additional contact with C65.30
Raltegravir and elvitegravir are very potent inhibitors 
of the IN strand transfer reaction with 50% inhibitory 
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Figure 2 Structures of raltegravir and elvitegravir. A) Raltegravir. B) elvitegravir. 
The  β-hydroxy  ketone  and  halobenzyl  moieties  are  indicated.  The  atoms  are 
indicated and/or represented by different colored spheres: C, gray; O, red; N, blue; 
Cl, green; F, brown. Hydrogen atoms are not shown. The chemical structures were 
created using MarvinSketch software (ChemAxon, Budapest, Hungary).Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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c  oncentrations in the nanomolar range.33 Both drugs possess 
good safety profiles and are rarely associated with severe 
adverse events. A significant Achilles’ heel for both drugs, as 
discussed in the next section, is a relatively low genetic barrier 
to the development of resistance such that a single mutation is 
enough to cause a major reduction in susceptibility. However, 
raltegravir and elvitegravir differ in their metabolic pathways, 
raltegravir being metabolized mainly by glucuronidation 
mediated by uridine-diphosphate-glucoronosyltransferase 
1A1, whereas elvitegravir is   metabolized by cytochrome 
P450 (CYP3A4/5) and   secondarily by glucuronidation.34 
As a consequence, the half-life of elvitegravir can be boosted 
by the coadministration of an inhibitor of CYP3A4 such as 
ritonavir.
Resistance patterns of IN inhibitors
Multiple mutations conferring resistance to raltegravir and 
elvitegravir have been described in vitro and in vivo in 
viruses from patients failing on raltegravir therapy. These 
mutations mostly involve amino acid substitutions that 
occur in the vicinity of the IN inhibitor-binding pocket in 
the CCD.31,32 Considerable cross-resistance has been demon-
strated between the two inhibitors which is not surprising as 
structural models have shown a similar binding mechanism 
for raltegravir and elvitegravir at the active site of IN.30,31 Pri-
marily, mutations causing high-level   resistance to raltegravir 
arise independently at three residues, namely Q148 (to H, R, 
or K), N155 (to H), and less frequently Y143 (to C, H, or R).12 
  However, mutations at T66 and E92 have also been shown to 
significantly affect susceptibility to both drugs when pres-
ent alone in vitro and in vivo, respectively.35,36 Predictably, 
these mutations negatively affect IN enzymatic activity, and 
therefore, viral replication capacity such that on the cessation 
of raltegravir treatment, the resistance mutations are quick 
to disappear,   demonstrating their impact on fitness of the 
virus.37,38 As a consequence, the primary mutations are often 
accompanied by one or more specific secondary mutations 
that either increase   resistance or restore viral fitness or both 
(Tables 1–3). Some of the   accessory mutations, such as L74I, 
T97A, E138K, V151I, G163R, V165I, V201I, I203M, and 
T206S, are natural polymorphisms which could influence the 
rate of development of resistance in viruses that contain 
these mutations at initiation of IN inhibitor therapy.39–43 The 
majority of these secondary mutations are also located in 
the vicinity of the IN active site (Figure 3C). Interestingly, 
only three IN residues where drug resistance mutations 
occur, namely Y143, P145, and Q146, were shown to contact 
raltegravir and/or elvitegravir in the structural models of the 
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Figure 3 Structure of the PFv IN active site. A) Structure of PFv IN active site 
within 14Å of Mn2+ ions showing location of the three active site residues (red 
sticks), three residues where primary resistance mutations occur (yellow sticks), 
and Mn2+ ions (green spheres). B) Structure of PFv IN active site in complex with 
raltegravir showing the three oxygen atoms (red spheres) of the β-hydroxy ketone 
moiety chelating the Mn2+ ions. The halobenzyl moiety (with brown fluoride atom) 
is seen stacked close to the cytosine (C) of the CA dinucleotide of the donor DNA 
strand (purple sticks) which results in the displacement of the terminal adenosine 
(A) and its 3′ hydroxyl group from the active site. C) Structure of PFv IN active 
site  within  20Å  of  Mn2+  ions  showing  location  of  some  of  the  residues  where 
secondary  resistance  mutations  occur  (cyan  sticks).  PFv  residues  are  indicated, 
and the corresponding HIv-1 residues are in brackets. The nontransferred DNA 
strand is shown as brown sticks. Protein data bank codes are 3OY9 and 3L2v,31 
and the diagrams were created using RasMol software (University of Massachusetts, 
Amherst, MA, USA).Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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HIV intasome in complex with the inhibitors.30   Mutations 
occurring at the other sites are hypothesized to affect the 
conformation of the active site indirectly, so perturbing the 
binding of the inhibitors while preserving IN enzymatic 
activity. IN resistance accessory mutations have also been 
described to occur in the CTD at residue S230, suggesting a 
direct role for the other domains in IN enzymatic functions. 
Indeed, the new HIV intasome model shows that IN–viral 
DNA interactions not only involve residues in CCD, but also 
the other two domains.
The Q148R/H/K resistance pathway
Q148 is located on the active site flexible loop,   consisting 
of residues 140–148 which is involved in CCD–DNA 
contacts (Figure 3A, B). Arginine, histidine, or lysine 
  substitutions at position 148 have been shown to reduce 
Table 1 Secondary resistance mutation patterns associated with 
Q148HRK
Associated secondary  
mutationsa
Effects on drug resistance or 
viral fitness of Q148 mutants
N17S33
N17S + G163R33,56
v54I + e138K + G140A72 Increases resistance to raltegravir 
and elvitegravir compared to 
addition of e138K + G140A; 
increases viral fitness
L63I + L74M + A128T +  
e138K + v151I72
L74M + G140A73
v79I + G140A + G163R40
e92Q + e138K + M154I33,56
T97A38
T112A + G140S + G163R40 Increases raltegravir resistance 
compared to addition of G140S + 
G163R
H114Y + A128T74 Increases elvitegravir resistance
T124A33,56
e138K/A33,40,42,56,72,74–76 Depending on Q148 mutation, 
increases resistance to raltegravir 
and elvitegravir; increases viral 
fitness
e138K + G140A72 Increases resistance to raltegravir 
and elvitegravir compared 
to addition of G140A alone; 
increases viral fitness
e138A + G140S + Y143H40 Increases raltegravir resistance 
compared to addition of G140S 
alone
e138K + G140A + S230R72 Increases resistance to raltegravir 
compared to addition of e138K + 
G140A
e138K + G163R33,56
G140A/S/C33,38–40,42,44,45,49,52,56,73,75–79 Depending on Q148 mutation, 
increases resistance to raltegravir 
and elvitegravir; increases viral 
fitness
G140S + N155H40,77,79
G140S + K156N73
G140S/C + G163R/K33,40,45,53,56
G140S + e170A79
N155H45,77
N155H + e170A79
S147G77
G163R33
Notes: aShown are mutation patterns found in the same viral sample during in vitro 
or in vivo selection using raltegravir or elvitegravir. Mutations present at baseline or 
containing mixtures by population-based sequencing were excluded. References are 
given for each pattern of resistance mutations.
Table 2 Secondary resistance mutation patterns associated with 
N155H
Associated secondary  
mutationsa
Effects on drug resistance or viral 
fitness of N155 mutant
v72I40
v72I + e92G40
L74M + e92Q + v151I + 
e157Q72
e92Q/A/G36,42,45,75–77,79 Increases raltegravir and elvitegravir 
resistance
e92Q + T97A75 Increases raltegravir resistance 
compared to addition of e92Q alone
e92A + G163R45
Q95K37 Increases raltegravir and elvitegravir 
resistance; increases viral fitness
Q95K + v151I37 Increases raltegravir and elvitegravir 
resistance compared to addition of 
Q95K alone
T97A40,75 Increases raltegravir and elvitegravir 
resistance; increases viral fitness
T97A + v125A + v151I40 Increases raltegravir resistance 
compared to addition of v125A + v151I
T97A + v151I40,45 Increases raltegravir resistance 
compared to addition of T79A alone
T124A + v151I33,56
v125A + v151I40
G140S45
G140S + Q148H40,77,79
Y143R/H40,75,77,79 Increases raltegravir resistance
Y143R + e170A79
Q148R/H45,77
Q148H + e170A79
v151I33,38,45,53,56,75 Increases raltegravir resistance
v151I + M154I78
v151I + G163R45,53
M154I53,78
G163R/K45,75,76 Increases raltegravir and elvitegravir 
resistance; increases viral fitness
I204T33,56
D232N75
Notes: aShown are mutation patterns found in the same viral sample during in vitro 
or in vivo selection using raltegravir or elvitegravir. Mutations present at baseline or 
containing mixtures by population-based sequencing were excluded. References are 
given for each pattern of resistance mutations.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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both the   susceptibility to raltegravir and elvitegravir as well 
as the replication capacity of the virus.42,44 Consequently, 
substitutions at Q148 often occur with the secondary 
mutations, such as G140S/A or E138K, which improve viral 
replication capacity (Table 1). These secondary mutations 
appear after the establishment of the codon 148 primary 
mutation, and the nature of the amino acid substitution at 
position 148 dictates the effect secondary mutations have on 
drug susceptibility or replication fitness.42,45,46 Fransen et al 
showed that on addition of G140S to a Q148R/H mutant, 
susceptibility to raltegravir was reduced further compared to 
Q148R/H alone.42 In contrast, addition of the G140S muta-
tion to Q148K increased susceptibility to raltegravir. This 
study also showed that the addition of G140S improved the 
replication capacity of Q148H/K mutants but not Q148R.42 
Another study went further to reveal that the G140S/A 
mutants alone impaired IN strand transfer activity without 
affecting the 3′ processing reaction.47 On the other hand, 
the Q148R/H/K mutants showed defective activities in both 
strand transfer and 3′ processing. Thus, it was hypothesized 
that substituting Q with R, H, or K (all of which have longer 
and bulkier side chains) alters the binding of the viral DNA 
to IN, therefore affecting both the strand transfer and 3′ pro-
cessing activities. However, complementation studies have 
demonstrated that only the G140S/Q148H double mutant 
was capable of restoring IN activities to almost wild-type 
levels and that this complementation only operates in cis. 
This suggests that this double mutant is the only mutant able 
to restore an active site for viral DNA, allowing 3′ process-
ing and strand transfer activities, while not re-establishing 
the raltegravir binding site.47 Hence, this may explain the 
evolution toward this replication efficient double mutant 
virus in patients failing on raltegravir treatment.
The N155H resistance pathway
The N155 residue is located on α-helix 4, close to active 
site acidic residue E152 involved in chelation of metal ions 
(Figure 3A). The mutation N155H is generally associated 
with lower raltegravir resistance than Q148 mutations, which 
may explain its eventual disappearance and replacement 
with either the Q148R/H/K or Y143C/H/R mutations during 
raltegravir treatment failure (Figure 4).42,48 This mutant has 
been shown to reduce the replication capacity of the virus 
by impairing strand transfer activity and to some extent 3′ 
processing activity.37,49 A mechanism by which the N155H 
mutant causes resistance to raltegravir has been reported by 
Grobler et al. They proposed that the N155 residue in the IN 
active site interacts with the residues responsible for binding 
the magnesium cations required for IN activity. As raltegravir 
binds to IN through interactions with these metal ions, 
mutation of this residue may prevent raltegravir from binding 
by disrupting the metal ion active site arrangement.50
Interestingly, studies have shown that the N155H 
pathway has a broad range of reductions in raltegravir 
susceptibility which is dependent on the type of s  econdary 
mutations that have also been accumulated (Table 2). 
  However, it has been suggested that the 155 pathway does 
not confer a stable state of raltegravir resistance regardless 
of the accumulated s  econdary mutations since the type of 
secondary mutations in a viral population containing the 
N155H primary mutation vary greatly over time.45 Among the 
INSTI resistance-associated secondary mutations, the E92Q 
mutation has been shown to preferentially occur with the 
N155H mutation by clonal analysis and also that the addition 
of the E92Q mutation to N155H results in further decreases 
in both replication   capacity and raltegravir s  usceptibility.42 
It was thus hypothesized that selection of E92Q after the 
Figure 4 Schematic representation of the evolution of raltegravir primary resistance 
mutations. Initially, mutations conferring resistance to raltegravir have been shown 
to primarily occur at residues Q148 and N155. Subsequently, switches from 148 or 
155 pathways to 148 or 143 pathways have been observed.
Table 3 Secondary resistance mutation patterns associated with 
Y143CHRK
Associated secondary  
mutationsa
Effects on drug resistance  
or viral fitness of 
Y143CHRK mutants
L74M + T97A40,53
L74M + T97A + S119T + e138D53
L74M + T97A + e138A40 Increases raltegravir resistance 
compared to addition of T97A 
alone
L74M + e138D78
T97A40 Increases raltegravir resistance
T97A + e138A40
T97A + G140D + G163R38
G140S40 Increases raltegravir resistance
N155H40,77,79
N155H + e170A79
Notes: aShown are mutation patterns found in the same viral sample during in vitro 
or in vivo selection using raltegravir or elvitegravir. Mutations present at baseline or 
containing mixtures by population-based sequencing were excluded. References are 
given for each pattern of resistance mutations.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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establishment of N155H in the virus is probably driven by the 
increase in raltegravir resistance rather than to compensate 
for replication capacity.42 However, a recent study by Fun 
and colleagues has shown that subsequent selection of the 
Q95K mutation by the N155H-containing virus resulted in 
increased raltegravir resistance as well as a partially restored 
replication capacity.37 Further addition of the V151I mutation 
resulted in reduction in replication capacity but an additional 
increase in raltegravir resistance, generating a virus with an 
overall higher level of fitness in the presence of raltegravir. 
Indeed, this triple mutant virus was shown to rapidly domi-
nate the viral population in one patient during raltegravir 
treatment failure.37
The Y143C/H/R resistance pathway
Similar to Q148, Y143 is located on the active site   flexible 
loop (Figure 3A, B). As mentioned earlier, residue Y143 
is one of a few residues that directly make contact with 
raltegravir when the inhibitor is bound at the active site.30 
Therefore, development of IN inhibitor resistance via muta-
tion of Y143 can be explained by a direct effect on inhibitor 
binding. As with the other resistance pathways, mutations at 
position 143 in the viral IN gene have been shown to increase 
resistance to raltegravir while reducing the replication capac-
ity of the virus.40,48,51 The level of raltegravir resistance associ-
ated with this pathway, however, is believed to be higher than 
that of the Q148H/G140S double mutant and other primary 
mutations.51 In vitro studies show that the Y143R/C mutants 
have impaired 3′ processing and strand transfer activities. 
The 3′ processing activity was more affected in the R mutant 
than the C mutant, whereas the strand transfer activity was 
more efficient in the R mutant. Regardless, both mutants had 
similar levels of resistance to raltegravir leading the authors 
to conclude that perhaps the Y143C mutant was a transient 
form of the Y143R mutant, as a Y to C change involves a 
single bp change, whereas a Y to R change requires two 
bp changes. Structural modeling analysis of the Y143R/C 
mutants suggested that these mutants may allow for an 
alternative recognition site for DNA binding, in particular, 
the post-3′ processing contact with the 5′AC overhang, while 
preventing the binding of raltegravir to the enzyme.51 In 
another study by Reigadas et al, the strand transfer activity 
of the Y143R/C mutants was shown to be severely impaired, 
but the 3′ processing activity was only moderately impaired. 
They showed that this mutant was highly resistant to ralte-
gravir but had a much lower replication capacity than wild-
type virus. Drawing on conclusions from unpublished data 
from Fransen et al,42 Reigadas and colleagues suggested that 
perhaps the protease and/or reverse transcriptase of the virus 
help to rescue this replication capacity deficit.48 Studies have 
shown that Y143R/C mutants can be present either alone or in 
association with other secondary mutations (Table 3). Little 
is yet known about the effects of these secondary mutations 
on the raltegravir resistance levels and replication capacity of 
the viruses expressing the Y143R/C mutations. Nonetheless, 
it is widely considered that these mutations play a positive 
role in IN activity and/or resistance to raltegravir.40,48,51
Several other IN resistance mutation patterns have been 
described that do not involve mutations at Y143, Q148, or 
N155 (Table 4). However, the three main resistance pathways 
described above have been shown to be mutually exclusive. 
Several studies have shown that the different pathways can be 
Table 4 Other integrase resistance mutation patterns
Other resistance  
mutation patternsa
Effects on drug resistance  
or viral fitness
H51Y + e92Q + S147G35 Increased resistance to elvitegravir 
compared to e92Q alone
G59e33
T66I/A/K33,56,74,80 Resistance to elvitegravir; resistance  
to raltegravir depending on mutation
T66I + v72A + A128T33,56 Resistance to elvitegravir
T66A + L74I + e92Q52
T66I + e92Q + T124A33,56 Resistance to elvitegravir
T66I + Q95K + e138K +  
Q146P + S147G35
Increased resistance to elvitegravir 
compared to addition of T66I +  
Q146P + S147G
T66I/K + T124A33,56 Resistance to elvitegravir
T66I + T124A + Q146L33,56 Resistance to elvitegravir
T66I + Q146P35 Increased resistance to elvitegravir 
compared to T66I or Q146P alone
T66I + Q146P + S147G35 Increased resistance to elvitegravir 
compared to addition of T66I + Q146P
T66I + S230R74 Resistance to elvitegravir
L68v/I + e92Q36 Increased resistance to elvitegravir and 
raltegravir compared to e92Q alone
e92Q33,35,42,49,56,74,80 Resistance to elvitegravir
e92Qv + T124A33,56 Resistance to elvitegravir
e92Q + M154I33 Resistance to raltegravir
T124A33,56 No resistance to raltegravir or 
elvitegravir
T124A + P145S33,56 Resistance to elvitegravir
T124A + Q146L33,56 Resistance to elvitegravir
P145S33,56,81 Resistance to elvitegravir
Q146P + N232D35 Resistance to elvitegravir
v151I33 Resistance to elvitegravir
e157Q49
S230N/R73,74 No effect on raltegravir or elvitegravir 
resistance
Notes: aShown are mutation patterns found in the same viral sample during in vitro 
or in vivo selection using raltegravir or elvitegravir. Mutations present at baseline or 
containing mixtures by population-based sequencing were excluded. References are 
given for each pattern of resistance mutations.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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present in the same viral population within patients undergoing 
virological failure albeit on different genomes.38,42,45,48,52 This 
suggests that a virus containing more than one of the primary 
mutations is probably severely impaired and replicatively 
compromised. Nonetheless, it has been suggested that the 
evolution of raltegravir resistance mutations is mostly driven 
by the need to increase levels of resistance during drug-
selective pressure rather than replication fitness.40,42 Indeed, 
a switch from the 155 to the 148 pathway is often observed 
during treatment failure   (Figure 4) and is believed possibly 
to be linked to higher levels of raltegravir resistance seen 
with the 148   pathway.45 Switches from either the 148 or 155 
pathways to the 143 pathway have also been observed during 
treatment failure.40,48,53 However, in this case, it is believed 
that the eventual emergence of the 143 pathway may be 
associated with its replicative advantage in the presence of 
raltegravir rather than an increase in resistance levels.44
Two second-generation INSTIs are in late stages of devel-
opment by GlaxoSmithKline (GSK) and Shionogi, namely 
S/GSK1349572 and S/GSK1265744.54 Of interest, the pattern 
of resistance mutations associated with S/GSK1349572 in 
cell culture passages was shown to be different from that 
seen with raltegravir or elvitegravir. Resistance mutation 
patterns associated with S/GSK1349572 included T124A, 
S153Y, T124A/S153Y, T124A/S153F, and L101I/T124A/
S153Y. S/GSK1349572 has been shown to either completely 
or partially inhibit raltegravir- and elvitegravir-resistant 
viruses in vitro.55–57 However, combination mutations involv-
ing primary mutations at Q148 and N155 have been shown 
to still cause a significant loss of activity although less than 
that observed with raltegravir. This suggests that these 
compounds have a similar mode of action to raltegravir and 
elvitegravir.
Use of raltegravir in clinical practice
Initially, raltegravir was approved for use in patients who 
had experienced treatment failure on previous regimens; 
however, it is now being considered for use in first-line 
regimens.58 Several studies have looked at the effectiveness 
of raltegravir in treatment-experienced and treatment-naïve 
patients.
Treatment-experienced patients
The BENCHMRK trial showed that raltegravir was highly 
effective in the treatment of patients when combined with an 
optimized background regimen. A total of 57% of patients 
receiving raltegravir had undetectable viral load (VL) 
(,50 RNA copies/mL) at 96 weeks, compared with 26% 
of placebo recipients who only received optimized therapy. 
The best results were seen when raltegravir was combined 
with two new active agents.59 Significantly, greater rises 
in CD4 counts were also seen in the raltegravir recipients. 
Thus, overall, these studies showed that raltegravir could 
contribute to long-term viral suppression in patients with 
multidrug-resistant HIV, provided that other drugs in the 
regimen were also effective.
Treatment-naïve patients
Raltegravir has been shown to be noninferior to efavirenz 
when combined with tenofovir and emtricitabine in the 
STARTMRK trial and was associated with faster virological 
responses.60 There have also been studies to examine the 
effectiveness of NRTI-sparing combinations where ralte-
gravir has been used with ritonavir-boosted lopinavir or 
unboosted atazanavir. The first showed similar outcomes to 
use of raltegravir with tenofovir and emtricitabine,61 whereas 
the latter was discontinued due to adverse effects and a 
higher number of virological failures.62 Thus, the combina-
tion of raltegravir with tenofovir and emtricitabine is now 
regarded as a useful possible alternative first-line therapy, 
although long-term experience with potential toxicities due 
to raltegravir have yet to be determined.63 A coformulation 
pill known as Quad, comprising of elvitegravir with a novel 
pharmacoenhancer called cobicistat (GS-9350) plus emtric-
itabine and tenofovir, is also undergoing clinical trials in 
ART-naïve HIV-infected individuals. In phase II trials, Quad 
has been shown to have similar efficacy and to be associated 
with less adverse effects compared to Atripla (efavirenz + 
emtricitabine + tenofovir).64
Switching therapies
Two trials, SWITCHMRK and SPIRAL, have looked at 
replacing PIs with raltegravir in suppressed patients, but only in 
SPIRAL was the raltegravir switch found to be noninferior.65,66 
The reasons for the different outcomes are believed to lie in 
the previous treatment histories of the patients and whether 
they had experienced virological failure before.
Future research and optimal use  
of existing and emerging agents
The development of HIV-1 IN inhibitors has been ongoing 
for nearly two decades, but success has been long time com-
ing, in terms of drugs approved for clinical use, with only 
raltegravir licensed for clinical use to date. In part, this is 
because the knowledge of how IN inhibitors work and the 
mechanism of IN drug resistance has been incomplete due to   Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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the lack of a crystal structure of HIV-1 IN alone or in com-
plex with inhibitors. The recent elucidation of the structure 
of the PFV intasome in complex with first-  generation 
INSTIs has helped produce better structural models of the 
HIV-1 intasome–INSTI complex.30,31 This is a significant 
event that will advance the strategic design and development 
of new active site inhibitors against both wild-type IN and 
drug-resistant IN mutants or spur improvements of existing 
INSTIs. Despite the close relation of PFV and HIV-1 IN 
proteins, structural differences do exist between the two, 
such as the presence of the N-terminal extension domain in 
PFV , which is involved in nonspecific DNA binding of viral 
DNA ends.31 Therefore, HIV IN drug design will benefit even 
more from the elucidation of a crystal structure of HIV-1 IN 
in complex with inhibitors, and that still remains a major goal 
for IN inhibitor drug design and development.
In addition to understanding the mechanism of inhibi-
tion and drug resistance profiles of available INSTIs, an 
HIV-1 intasome model or crystal structure will enable the 
development of inhibitors that can target other IN regions 
apart from the active site, akin to the development of RTIs. 
Zidovudine was the first RTI developed as a competi-
tive nucleoside analog inhibitor that blocked HIV-1 DNA 
  synthesis by binding at the polymerase active site.4 Following 
its discovery, structural modeling played a prominent role in 
the design and development of non-nucleoside inhibitors that 
bound outside the polymerase active site.5 This new class 
of inhibitors blocked HIV-1 DNA synthesis by affecting 
the conformation of the active site, a feat better understood 
with the help of structural models.5 As mentioned earlier, 
the discovery of this new class of ARVs prompted the use of 
combination therapy as the resistance mutation profiles for 
the two classes are mutually exclusive. It is, therefore, envis-
aged that understanding the structure of the HIV-1 intasome 
could fuel the search for agents that inhibit HIV-1 integration 
by binding outside of the IN active site and/or by a different 
mechanism, which can then be used in combination with 
first-generation INSTIs, raltegravir or elvitegravir.
With that goal in mind, several avenues for the discovery 
of IN inhibitors are already being explored and could produce 
future drugs in addition to the first- and second-generation 
INSTIs.32 Other reactions or interactions involving IN, apart 
from the strand transfer reaction, could provide potential 
targets for blocking HIV-1 integration. These include the 3′ 
processing reaction, the interaction of IN with both viral and 
target DNA, the dimerization or oligomerization of IN, and 
the interaction of IN with host or viral cofactors. Several such 
agents have been discovered in the past few years, but some 
of these have not been developed further partly due to a lack 
of an understanding of their mechanism of action. Structural 
models of these inhibitors in complex with an HIV-1   intasome 
can lead to improvements in their design and alternative 
means of inhibiting HIV-1 DNA integration.
The holy grail for HIV therapy is the complete eradica-
tion of the virus in infected individuals; however, this still 
remains elusive. Studies on viral eradication have shown that 
the reduction of VL in infected individuals during effective 
HAART occurs rapidly during the early phases. However, 
the later phase involves a further gradual and long-term 
reduction in VL with estimates of more than 60 years for 
complete eradication of the virus from the infected individual 
to occur.67,68 It is believed that the latency of HIV-1 infection 
and probably the persistent low-level expression of nascent 
virions from long-lived cells infected prior to commencement 
of HAART could be significant bottlenecks to achieving 
eradication. One strategy, which has been attempted, is ARV 
treatment intensification with or without the use of selective 
inducers of HIV-1 expression. Raltegravir has been one of 
the ARVs chosen for intensification therapy partially because 
it has been documented to produce an accelerated decay of 
HIV-1 RNA in infected individuals. This is believed to result 
from improved distribution of raltegravir to less accessible 
sites and cells capable of producing HIV-1 particles, such 
as in the cerebrospinal fluid.69 However, preliminary results 
have proved disappointing with unsustainable reductions of 
residual HIV-1 viremia and no eradication of the virus.70,71 
In the future, intensification treatments could involve the 
use of raltegravir or novel IN inhibitors with or without 
more potent inducers of HIV-1 expression. Other areas of 
raltegravir use being investigated include prevention of 
perinatal infection and postexposure prophylaxis.
Conclusions
The pattern of development of resistance to INSTIs has been 
extensively investigated. Three primary mutations occurring 
independently at residues Q148, N155, and Y143 result in 
high-level resistance to first-generation INSTIs. These muta-
tions are often accompanied by other mutations in IN which 
increase resistance and/or improve replication capacity of 
the virus. Multiple cell-based and biochemical assays have 
been used to understand the effects of the mutations associ-
ated with resistance to INSTIs. The recent availability of the 
structural model of an HIV-1 intasome that has been obtained 
following the elucidation of the crystal structure of the PFV 
intasome has significantly augmented the understanding of 
the mechanisms of resistance to INSTIs. The availability Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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of the HIV-1 intasome structural model will undoubtedly 
bolster the strategic design of new inhibitors and will help 
predict how HIV-1 might evolve resistance to the drugs. The 
structural model could also allow improvements to be made 
to existing IN inhibitors with the goal of reducing the chances 
for the development of resistance.
The increase in the classes and numbers of ARVs, which 
now includes IN inhibitors, has significantly   contributed 
to the success of HAART. This has allowed the complete 
suppression of viral replication in infected   individuals, 
resulting in undetectable HIV-1 RNA levels of ,50 
copies/mL. This can be achieved not only in ART-naïve 
  individuals, but also in individuals who have experienced 
treatment failure on previous regimens. An understanding of 
the   evolution of drug resistance in the new classes of ARVs is 
crucial to maintaining or improving on this success as well as 
in the design of next generation drugs in these new classes.
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